UNIGE document Scientific Article
previous document  unige:79578  next document
add to browser collection
Title

Repenser la politique de remboursement des agents antiviraux directs contre l’hépatite C chronique

Authors
Published in Revue médicale suisse. 2015, vol. 11, no. 484, p. 1610-1614
Abstract New direct-acting antivirals (DAA) against hepatitis C virus (HCV) have led to a therapeutic revolution in HCV management and virological cure rates approaching 100% while potentially avoiding significant complications of HCV (first cause of liver transplantation). We estimated the price of sustained virological response (SVR) depending on treatment strategy and patient profile. Costs of treatment with recent DAAs being so high, the accessibility to those drugs for the majority of subjects is hitherto limited to advanced stages of hepatitis C. This current situation increases the inequity and strengthens the dominant position of insurers and pharmaceutical companies with a rationing of care. We suggest herein global approaches from a population-level and health-care perspective aiming to reduce the prevalence, morbidity, and mortality related to HCV.
Identifiers
PMID: 26502622
Full text
Article (Author postprint) (503 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Structures
Research groups Etudes et traitement de l'hépatite C et B (554)
Groupe Desmeules Jules (pharmacologie/toxicologie) (567)
Citation
(ISO format)
GIRARDIN, François et al. Repenser la politique de remboursement des agents antiviraux directs contre l’hépatite C chronique. In: Revue Medicale Suisse, 2015, vol. 11, n° 484, p. 1610-1614. https://archive-ouverte.unige.ch/unige:79578

99 hits

0 download

Update

Deposited on : 2016-01-19

Export document
Format :
Citation style :